Meeting Proceedings of the “Phase I: Where Science Becomes Medicine” Conference, Manchester, UK

Donna M. Graham1,2,3, Louise Carter1,2,3, Matthew G. Krebs1,2,3, Duncan Jodrell4, Anne Armstrong2,3, Elaine Kilgour1,2,5, Tim Illidge1,2,3, Joseph Clarke,2 Rachel Chown2, Kaye Williams1,2, Caroline Dive1,2,5, Janelle Yorke1,2, Clare Dickinson2,3, Andrew Hughes1,2,5, Fiona Thistlethwaite1,2,3, Rob Bristow,1,2,3 Natalie Cook1,2,31Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, 2Manchester Cancer Research Centre, Manchester, UK, 3The Christie NHS Foundation Trust, Manchester, UK, 4Cancer Research UK Cambridge Institute (CRUK), University of Cambridge, Cambridge, UK, 5CRUK Manchester Institute, Manchester, UKPhase I clinical trials are the gateway to establishing new treatments for cancer patients by translating preclinical scientific advances to the clinic. The traditional Phase I design has involved small groups of patients, investigating toxicity and patient safety, and the pharmacodynamic and pharmacokinetic activities of novel treatments. Recent years have seen a rapid evolution in the scope and conduct of Phase I trials.The “Phase I: Where Science Becomes Medicine” conference, was held between the 14th and 16th of July 2019 in Manchester, UK with a dedicated focus on Phase I cancer trials and an overview of the dynamic landscape of the field. Global experts presented and discussed the key issues facing Phase I clinical triallists in a city with a long history of drug development and translational cancer research.Discussions were held across 10 sessions on a range of interlinked topics related to Phase I clinical trials. These included: novel drug targets and their impact on trial design, biomarkers and precision medicine, immunooncology, radiotherapy combinations, advanced therapies and trial methodology. The conference involved a mixture of plenary lectures, keynote speaker sessions, debates, poster presentations, a parallel nursing workshop, and exhibitions from various organizations.Over 220 delegates attended the conference with global representation. Delegates had diverse backgrounds spanning academia, industry and International professional healthcare bodies. Each session of the conference commenced with a video featuring patients’ and caregivers’ voices. These detailed first-hand accounts of how cancer and clinical trials affect participating patients and their families and provided a reminder of the importance of these trials and a focus for each session. In addition, 31 abstracts were accepted to be presented as posters and are included in the conference proceedings. Prizes were awarded to the top five posters (abstract numbers 7, 8, 18, 20 and 26).The meeting was opened by Professor Robert Bristow and Dr Natalie Cook who described the vision for the Phase I program in Manchester and the changes in cancer treatments over recent years. This included the increasing use of personalised therapies and genomic profiling, incorporation of novel combination therapies and the use of radiotherapy within a real-world evidence clinical database.Professor Lillian Siu, Chair of the Drug Development Program at Princess Margaret Cancer Centre in Toronto, delivered the first keynote of the conference, presenting “Phase I: Past and present”. She gave a fascinating overview of the evolution of Phase I clinical trials with novel designs, increasing patient numbers, incorporation of biomarkers and the emergence of immunotherapy as areas of change over recent years. Alongside these changes, Phase I trialists are also carrying the responsibilities of Phase II and III triallists due to the evolution of trial design. Despite this, the critical endpoints of safety and establishing recommended Phase II dose remain. Professor Siu highlighted a shift in trial design, where patients play an increasingly important role in both the development of and participation in Phase I trials.Dr Howard (Skip) Burris, Chief Medical Officer and Head of the Drug Development Programme of the Sarah Research Institute and 2019 of the of detailed the for Phase highlighted the of Phase I trials at the recent meeting and critical of biomarkers for drug and of patient also the role of real-world for patient and the to the Phase I to how for trials be to for a of the patient to of and to the drug and biomarkers were the focus of the where the cancer patient have genomic to each was by Dr who and Professor who the were delivered from Dr Donna and Dr Matthew and of of drug the emergence of as a and for patients, a to profiling, to clinical and The in of genomic to each session on novel targets and the impact on trial on the of Phase I trials. Professor the with an of how targets have the and conduct of clinical trials. Professor Sarah on of the and in the UK trial Dr the session by the drug development the of and between new and to design the patients important for of The and patient the drug development and and the importance of and biomarkers in clinical focus of the conference was the role of biomarkers for precision Professor Caroline discussed the to a and the development of the This to genomic and trial to the genomic of the Professor highlighted in to patients to trials the trial for cancer this, Professor detailed the role of in for key of session was the for and biomarkers to development of new precision session of on Dr from provided an overview of the immunotherapy and the by combination The of immunotherapy was by Dr who highlighted the of clinical trials and the scientific development of Dr the session by and as targets for novel This session the to for and the role biomarkers play in combination of the conference with a the and of radiotherapy drug in Phase I trials. Professor Kaye how had with the and to a on the clinical development of new The has the UK experts across immunotherapy and Professor on the role of the and Phase on novel in and Professor delivered an of the translational of trials by preclinical investigating the combination of radiotherapy with for the of and session on trial development across a range of discussed the use of therapies for Dr on to the use of in Dr described the development of a Phase I trial in for patients with and session a and diverse range of the of to in increasingly to use as the key to in parallel with the conference was a Cancer Research UK nursing of Research in the Development of Phase I The session was and the of Phase I trials and the these changes have for clinical and their The speaker a and and within the Dr also the drug development and Professor Janelle highlighted the role of as and with for of the conference were debates, where the on changes in Phase I clinical trials. The the Professor a of to and who have to design, Professor these trial over designs, in a of a dose was to be in of drug Phase I be the was the to the Dr discussed how patients as a of to patient and on Phase I trials. Dr Donna discussed a program for patients the for clinical trial was also the of the of and trial the the of Phase was to the Professor the focus for Phase I to the recommended dose range for Phase II trials as a dose be recommended from Phase In Professor the focus be on drug of the use of trial from session trial design for Phase and be by to for in Phase I clinical trial designs, by the and to between the to the drug in Phase the and of Phase I the of to and a Andrew the conference by the importance of Phase I trials as the to for cancer These trials the first as to the the patients and the highlighted of the from the patient was Phase I trials a of for patients and their families and on a key for the Phase I the Cancer Centre The Christie NHS Foundation Trust, Institute for Research Tim and Rob Bristow are by the Manchester Research M. G. University of UK, Cancer Medicine Centre, University of UK, Cancer Medicine Centre, University of UK, of and UK, of and Institute of Cancer Research and UK, Institute of Cancer Research and UK, Cancer Research UK, UK, The Medical University of In of a of the an Cancer Medicine clinical trial to a recommended II dose and to with the with and for to dose was dose toxicity in of The was to cancer due to endpoints included pharmacodynamic and pharmacokinetic in of patients in in of patients in and of patients and and and in endpoints of and for and were with were with with the in combination with dose as for cancer Anne of and Research University of Science at of of with the novel the of of has to This was to the dose of patients with who were the was in toxicity were by were for and by in in and with in and in and in The of was in combination with patients in had of their in and on the of in to at with and in and an as in development for to of important as Phase trial of and pharmacokinetic are in as a and with to the of as with of in with and the of with of In the patients with were with of in the and was and was evidence of were toxicity The of and In by with in was dose of In patients with at of with at was of was a dose of of was and for and with as an of was to the of as an trial for Robert of The University of of Cancer University of Cancer a has an clinical and in patients who The novel with novel was Drug by the for the of in This a to the and with for for the of with from the first patients of the within of were and patients had patients over years of the clinical are a shift in the of patients with and to an in the of Anne of Medical of Medical University of Medical of Medical University of University of Medical University of an for to to and has due to by in the of a novel of with the of the of an clinical and of in of cancer of for for was at and was at and in was for patient were was years the of at was at to to patients were for were and in patients had and patients with a novel of in patients who with and to of Science and of of and Research Institute, Cancer of a role in due to in be a are to for clinical and as the and of in a and a a and the of with with the in combination with the in and in of in both and are in be a for with also the use and in combination be a for both and are for and with Matthew G. Cancer Medicine Cancer Research UK Manchester Institute, Manchester, UK, Christie NHS Foundation Trust, Manchester, UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, The trial to patients to clinical trials on their from and of clinical and the of for the and of clinical and genomic the of of were in and by The genomic were with the clinical in a were from the and and were on and were to as new of for patients were included in on the of in between and and of to were in a of and of has key with These the to as new from to to and the to and of Sarah Matthew G. and Cancer Research UK Manchester Institute, Manchester, UK, Christie NHS Foundation Trust, Manchester, UK, The University of Manchester, Manchester, UK, Centre for Manchester University NHS Foundation Trust, Manchester, UK, UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Cancer Research Centre has an to precision within the trial to The to clinical and from and for patients for clinical trials. the on a clinical and genomic to and by the was in a included for from a for and the and a with clinical to the The of clinical and genomic has at and patient have has the to patient in a and trial and the meeting to the patient The be where the Recent have included a to patients with genomic of the of from Foundation Medicine and the to changes in on has the of from in by presenting a of patient clinical and genomic have the of in a to for an The the of participation Elaine Andrew Cancer Medicine Manchester Institute, The University of Manchester, Manchester, UK, Christie NHS Foundation Trust, Manchester, UK, UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, and Cancer Research UK Manchester Institute, Manchester, in are and to has the to change how clinical trials. of to be and in trials clinical development The of was to the of establishing a clinical trial within a clinical trials of a within the clinical at The Christie NHS Foundation of the landscape and University of Manchester and NHS Development of a and for in patients, to of and were for a and for trials and the first trial to clinical trials. has in an clinical trials clinical trials a clinical with and a role for new and are to be to clinical Medicine and Cancer Research UK Manchester Institute, Manchester, UK, The University of Manchester, Manchester, Phase clinical trials are the and drug development and the and of of changes to these trials are for to the patient drug combination and the of This the for to trial to and a clinical trial and with an of of clinical safety and has the to the to in the and the for new cancer treatments with the also the for and of at has delivered to and by the Cancer Medicine the have by clinical and genomic has of across the patient in a genomic and of changes in the has to an genomic for patients of to the trial to involved in clinical both from the and focus on and both the patient by the and drug development by the trial Cancer Medicine Cancer Research UK Manchester Institute, The University of Manchester, Manchester, to cancer clinical trials and to patients with The and a by clinical in to for both a who have cancer and The of was to new advances in of and and patients the to in trials. an the and of a a and an to and the first in traditional and clinical trial design. were for and was and to a and patient was over a with and with a focus The was due to and The design was with patients on patient be by the This of be by a the an and in clinical trial has and to clinical of to to the cancer Andrew M. Donna M. Cancer Medicine The Christie NHS Foundation Trust, Manchester, UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, in healthcare with the NHS of clinical an to in clinical trials a This the use of a for use in an clinical trials trial was and a to use of for of on the Medical and nursing and of use of the Manchester was in to dedicated from nursing and This a of use on the The use of to in and of with patients an in of of the and of clinical in a and of be This as a in the of for clinical and Cancer Centre, University UK, of and The increasing of drug development has seen in trial Research on to has the of an important in to the of for trial designs, for I and from 31 between on for I and to how to novel at the of these on of to for for I trials. of across were of in to be with was for 31 for for for various I trial for toxicity and and to for in the of design in I trials. are for trial Research Institute at Cancer Institute of Cancer on Phase with their by trial trial have and clinical from and and The recent of designs, to clinical and the design to of a of Phase trial design. from trial their and these as for a a described a these use cancer to the with patients in I the drug at change the use for a to the the to an evidence with clinical This of in both dose and of toxicity as a to in trials. by cancer trial and their to in Phase dose with an the of how a on for from a an to a in of the of to be an of dose to to with the the a of the patients a dose at and for a to for a and with by the for the and over as a a with The at to be a of the the of the of The of the at for to of a This the importance to of dose in these to patients, and as a G. of Medical of of University of Medical of University of Medical to the of precision and for in the to genomic genomic medicine, and clinical trials. The the in each of the to in the has the to the to healthcare medicine, and are M. Margaret Cancer Centre, University University of Toronto, Toronto, a of of as the and are This to the of these in patients in clinical trials with immunotherapy in trials at Princess Margaret Cancer Centre between and were from the and of and were and with and and were with and on the were was and had trials were and The were and of of and and were and with for both and in and and were with in a for and with of and for as was with in a and are with in in Phase Medical with for This the of for were with for and and were with and of and areas were with the was and by on and were to a to of each were with from and were for of in and in the of and in the of from the from each and from the of and between the a within the of have of for of for and areas in and between were by These the of as a for Andrew Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, of Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, Cancer Research Centre The Christie NHS Foundation Trust, Manchester Institute, Manchester, UK, Cancer Research Centre, Institute of Cancer Sciences, The Christie NHS Foundation Trust, University of Manchester, Manchester, The development and of cancer novel to the of the with the The of biomarkers from due to the range of the use of as an to cancer in the and to to the of with also as in to the of for cancer were with from patients and and were and between and by of the of the to novel biomarkers with and the in have the to be as an for This to the for to the clinical of as a novel to over and of novel biomarkers for and M. Cancer Research of University of cancer a with a genomic landscape and the of for cancer patients, with to small of of the in the the for therapies to and the for preclinical and clinical the of and drug have novel drug targets and for of These new therapies for and of these therapies by have to the and of their from are with and drug to are biomarkers of to clinical development of these novel have the and clinical of of to and for This has patients to be with are for have a drug development and these and to precision for cancer Robert of Cancer Sciences, University of Manchester, Manchester, UK, Medical University of Cancer Research Centre, The Cancer Research Manchester, increasing in radiotherapy in of genomic and development in The due to with of and Recent clinical trials to biomarkers have a to for and the for was for The was for in in The was to the for and for to were from patients between and the of were from patients in were to the for the was an and was in and The was was with the a of with The had an of and a of the with a of for the the on the with to on the and the of a The for the The was to and for of a in with the of for NHS within the Trust, to a to of patients with The patients a NHS have their to their and an to trial the are in to to the NHS in NHS of of the who had had a was The of patients with from the was also These were and were for the to the for each were for were the and The of the was of The to for was of the are for to on and of of patients with to be with to of patient groups in Natalie Fiona Louise Donna of Cancer Sciences, University of Manchester, Manchester, UK, Christie NHS Foundation Trust, Manchester, to the and clinical of cancer patients to the Cancer Medicine at the Christie for of clinical trials was on patients to the over 10 in was from cancer and history and years of a with the cancer patient The of patients were and were from the of of at was of patients in areas from the to was This the of areas within The of in the was by and had a of of to the patients were for with the and the patients for clinical trials were to and were for patients with advanced of to the in patients and from and areas were the for these and to important areas for Matthew Louise Donna Fiona Natalie Cancer Medicine The Christie NHS Foundation Trust, Manchester, UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, of patients to clinical cancer trials to the trial who these are patients at The Christie NHS Foundation a in an patient an of changes were to The of was to the were from a of patients to an was from patients to between for were and and were to of of was In the the cancer were and for included in patients, patients with a new of rapid and each in of issues and trial each in of to were by in and by in were in to in the to in This the impact of The be on a for Matthew Janelle Christie NHS Foundation Trust, Manchester, UK, Manchester and Manchester University NHS Foundation Trust, Manchester, UK, of and UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, of and of Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, The and role of from a traditional of of to of In recent a for advanced cancer patients has recommended are their cancer the of in a I trial the to patients’ and their of was to advanced cancer patients who had to the I clinical trial were and were with a to and from cancer and cancer Despite this, a for of the role of was and to provided at of was between a I trial and a I trial for the was at with with of be and to patient of and with advanced cancer for I trials are to from patients a for due to the role of a for to with a G. Christie NHS Foundation Trust, Manchester, UK, The Christie NHS Foundation Trust, Manchester, UK, of Biology, Medicine and Health, The University of Manchester, Manchester, to the of patient in clinical trials. to the for Cancer Medicine the for the development and of I: and focus groups and to the be to with the for and be the in I and II have I Phase Phase and recommended the development of of trial and trial be in Each the to participation trial of and for The be the first for cancer clinical trials. on have the of an for Cancer Medicine The Christie NHS Foundation Trust, Manchester, UK, of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, Research UK, Manchester, UK, Manchester Research Centre, Manchester, UK, Manchester University NHS Foundation Trust, Manchester, a patient and with with cancer and precision of of and and participation The was held on to with Cancer The presentations, of the Research and by an The was The and was video and from at the of the and a of of to their the of an trial as a of the of the between and and the at the by the were and to for and The a between and the for and are important to This has a shift from the the and from has to of to clinical Manchester Research The Christie NHS Foundation Trust, Manchester, The Christie the for of by The Manchester Centre to the of of by trials as to as drug trials. and an of these The Christie Research has in was was a trial the of an was seen as This has the development of a and has over nursing for a of the clinical with and a to clinical and are from for and of have the in in the of of at and The and are the to Research and at Research The Christie NHS Foundation Trust, Manchester, UK, Christie NHS Foundation Trust, Manchester, UK, of Cancer Sciences, The University of Manchester, Manchester, trials are to This due to the of the These trials are to and be with In to the of the Christie Institute for Research Research has an and This has by Manchester Centre a Manchester awarded from UK with the of of of the patient a a of has provided a to the development of the with a focus a of the and Research a of a an of an has and key with are small of are to The has UK and have from the Christie The Christie the in an UK was to of and a of The a role in from for key new to the has for trial M. Cancer Medicine Centre, The Christie NHS Foundation Trust, Manchester, UK, and NHS Foundation Trust, Research UK, Manchester Research The Manchester Manchester, UK, Research The Christie NHS Foundation Trust, Manchester, a of by a of and by a the of advanced for advanced clinical in the the in UK clinical in clinical scope to a of the development of role to be due to issues to of clinical a of in the UK, a of in Research was in The to the of the role and to and the has and by the UK Research the Institute for Research have also these increasing and of the role from Research across the UK, the importance of and of The UK clinical to with the key professional of the role parallel the of the role across the from the in Research The Christie NHS Foundation Trust, Manchester, UK, 2Manchester Cancer Medicine Centre, The Christie NHS Foundation Trust, Manchester, the in the to and have an of the healthcare for years and a recent are between and in are an of clinical and to clinical trial by as a advanced within clinical in the for the of these in clinical related to of by key the to to cancer in the to how these have and The Cancer Centre and The Cancer Research are a of the healthcare and the are an of clinical in both to the clinical of trial and are as are across The Christie Manchester Research was the first in the UK to a in and has to the The and by with in clinical and to the to to advanced

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.